血浆p-tau217对认知正常老年人进展为认知障碍的预后价值
本研究汇总北美、日本和澳大利亚6个队列共2684名认知正常老年人的纵向数据,评估基线血浆p-tau217与认知障碍进展风险及认知下降速度的关系。结果显示,基线p-tau217每升高1个标准差,认知障碍进展风险增加(HR 1.38,95%CI 1.30-1.46),高水平和极高水平组5年绝对进展风险分别为24%和38%,且与更快的认知下降相关。
要点
- 血浆p-tau217升高与认知正常老年人进展为认知障碍的风险增加独立相关。
- 基线p-tau217高水平(1.1-2.4 SD)和极高水平(>2.5 SD)者5年绝对进展风险分别为24%和38%。
- p-tau217升高者认知下降速度更快,支持其用于预后模型开发与试验设计。
核心结论
- 在多个认知正常老年人队列的汇总样本中,较高的血浆p-tau217水平与临床进展风险增加和认知下降加速持续相关。
- 研究提供了时间特异性的绝对风险估计,支持p-tau217用于预后模型开发的潜力,并对未来试验设计有直接意义。
研究设计与样本
- 纵向队列研究,汇总来自北美、日本和澳大利亚6个观察性与临床试验队列的2684名认知正常老年人(认知正常定义在各队列内确定)。
- 最早入组时间为2004年,最近随访至2025年;中位随访5.4年,最长随访13.5年。
主要发现
- 共发生478例进展为认知障碍事件;基线p-tau217每升高1个标准差,进展风险增加(HR 1.38,95%CI 1.30-1.46)。
- 调整包括β-淀粉样蛋白PET Centiloids后关联仍显著(HR 1.32,95%CI 1.24-1.41)。
- 基线p-tau217高水平(1.1-2.4 SD)和极高水平(>2.5 SD)者5年绝对进展风险分别为24%(95%CI 20%-28%)和38%(95%CI 33%-43%)。
- 极高水平组5年 latent PACC 年化下降为-0.07单位/年(95%CI -0.10至-0.05),低水平组为0.03单位/年(95%CI 0.02-0.04)。
关键数值与推荐
- 主要结局为进展至认知障碍的时间(轻度认知障碍、痴呆或连续2次全局临床痴呆评定量表评分≥0.5)。
- 次要结局为 latent 临床前阿尔茨海默认知复合评分(PACC)的纵向变化,分值越高表示表现越好。
- 总体样本基线 latent PACC 评分范围为-0.8至2.7。
临床怎么用
- 血浆p-tau217可作为认知正常老年人认知障碍进展风险的预后分层指标,辅助试验入组与随访设计。
- 绝对风险估计需在未选择人群中进一步验证后,方可用于个体预后判断和临床决策。
局限性
- 样本来自多个经过选择的队列,需在未选择人群中进一步验证以支持个体预后与临床决策。
- 10年及更长期的绝对风险估计受数据有限制约。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Blood-based biomarkers for Alzheimer disease, particularly plasma phosphorylated tau 217 (p-tau217), accurately reflect early Alzheimer disease brain pathology in cognitively unimpaired individuals, but estimates of absolute risk of progression to cognitive impairment across multiple cohorts are needed. OBJECTIVE: To estimate absolute risk of progression to cognitive impairment and rates of cognitive decline based on plasma p-tau217 across cognitively unimpaired older adults. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal cohort study using harmonized data from 2684 cognitively unimpaired older adults (defined within cohort) across 6 observational and clinical trial cohorts based in North America, Japan, and Australia. The earliest enrollment was in 2004, with most recent follow-up in 2025. EXPOSURE: Baseline plasma p-tau217. MAIN OUTCOMES AND MEASURES: The primary outcome was time to progression to cognitive impairment (mild cognitive impairment, dementia, or 2 consecutive global Clinical Dementia Rating scores ≥0.5). The secondary outcome was longitudinal change on the latent Preclinical Alzheimer Cognitive Composite (PACC; higher values indicate better performance). RESULTS: Among the 2684 participants (median [IQR] age, 69.6 [66.2-74.2] years; 1697 [63%] female), there were 478 events of progression to cognitive impairment over a median follow-up of 5.4 years (maximum follow-up of 13.5 years). Each 1-SD increase in baseline p-tau217 level was associated with an increased risk of progression to cognitive impairment (hazard ratio, 1.38 [95% CI, 1.30-1.46]), and the association remained significant after adjustment, including β-amyloid positron emission tomography scan Centiloids (hazard ratio, 1.32 [95% CI, 1.24-1.41]). Participants with high (1.1-2.4 SD) and very high (>2.5 SD) baseline p-tau217 had 24% (95% CI, 20%-28%) and 38% (95% CI, 33%-43%) absolute risk of progression over 5 years, respectively, and risk was markedly higher over 10 years, although longer-term estimates were constrained by limited data. Elevated p-tau217 was also associated with faster cognitive decline based on change in latent PACC score. Among the overall sample, baseline latent PACC scores ranged from -0.8 to 2.7. The 5-year annualized decline for the very high p-tau217 group was -0.07 latent PACC units/y (95% CI, -0.10 to -0.05), relative to 0.03 units/y (95% CI, 0.02-0.04) in the low p-tau217 group. CONCLUSIONS AND RELEVANCE: In a pooled sample of multiple selected cohorts of cognitively unimpaired older adults, higher plasma p-tau217 levels were consistently associated with increased risk of clinical progression and accelerated cognitive decline. By providing time-specific absolute risk estimates, these findings support the potential of p-tau217 for prognostic model development, with direct implications for future trial design. Further validation in unselected populations is needed to inform individual prognosis and clinical decision-making in cognitively unimpaired individuals.
引用
- Buckley RF, Townsend DL, Birkenbihl CJ, et al. Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment. JAMA. 2026. PMID: 42449500. doi:10.1001/jama.2026.12556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。